They showed that in a humanized mouse model of HER2‐positive breast cancer, the site‐specific bioconjugation not only increased the homogeneity and repeatability of the radioimmunoconjugates but also decreased their binding to human and murine FcγRI and improved their tumor uptake and contrast.[52]. Here, ERBB2 is linked to neoplasm.